Cardiff Oncology Inc. (CRDF) Price to Earnings Ratio

Cardiff Oncology - graphic logo of issuer CRDF

Cardiff Oncology, Inc. (CRDF) fully outsources its production and clinical trials to external partners, while its bet on a unique PLK1 inhibitor to combat colorectal cancer will provide the company with significant pricing power. This price chart on GURU.Markets captured a value of -1.50, however, the business's financial health critically depends on the success of a single drug, creating a serious risk of single-product dependency.

Cardiff Oncology Inc. (CRDF) - Price to Earnings Ratio from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for cardiffoncology.com (CRDF)

- price and consensus price forecast:
Comprehensive company analysis:CRDF (Cardiff Oncology Inc.)
Product sample of Cardiff Oncology, Inc.

Assessing the asset quality of Cardiff Oncology, Inc. (CRDF) requires an analysis of profit capitalization efficiency. This price-to-earnings ratio reflects the number of years required to recoup investments through the business's net income. For the developer of onvansertib, this indicator confirms the fairness of the market valuation relative to the potential of targeted therapy. A stable coefficient, combined with future cash flow, ensures the sustainability of the invested capital.